Current Salvage Therapy Options for Relapsed/Refractory CLL
Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including a newer therapy coming down the pipeline now.
Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including a newer therapy coming down the pipeline now.
Based on findings from clinical trials, Kay says the 4 major salvage therapies right now include ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib(Zydelig)/rituximab (Rituxan), and allogeneic bone marrow transplant. While it remains unclear in which order to administer these treatments, a wise decision can be made based off a patient’s age, comorbidities, and treatment goals.
